Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia

Blood. 1993 Jun 1;81(11):3022-6.


The p53 gene is currently thought to be a tumor suppressor gene, and its alterations have been suggested to be involved in the pathogenesis of several human malignancies, including some leukemias and lymphomas. We present here evidence for the possible involvement of p53 gene mutations in the myelodysplastic syndrome (MDS), although the incidence is relatively low. Forty-four patients with MDS and six patients with overt leukemias that developed from MDS were studied for p53 gene alterations using reverse transcriptase-polymerase chain reaction, single-strand conformation polymorphism analysis, and nucleotide sequencing. Three patients with MDS (2 RAEB and 1 RAEB in T) had missense point mutations in the conserved regions of the p53 coding sequence. Furthermore, expression of the wild-type p53 mRNA was not detected in these three patients. The probable absence of normal p53 function in the three cases studied here suggests that alterations in the p53 gene may occasionally play a role in MDS. These three MDS patients with p53 gene mutations and an MDS-derived erythroleukemia cell line that we had previously reported to carry a p53 gene mutation showed no N-ras gene mutations, suggesting heterogeneity in the oncogenic mechanism of MDS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Base Sequence
  • Chromosome Aberrations / genetics
  • Chromosome Disorders
  • Gene Expression
  • Genes, p53*
  • Genes, ras
  • Humans
  • Karyotyping
  • Leukemia / genetics*
  • Mutation
  • Myelodysplastic Syndromes / genetics*
  • RNA, Messenger / genetics
  • RNA, Neoplasm / genetics


  • RNA, Messenger
  • RNA, Neoplasm